There is only one approved use (also called "indication") for
Synagis® (
palivizumab): to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (
RSV) in infants and young children who are at high risk for this infection.
This medication is not approved for use in adults; it has only been studied in children age 24 months and younger. It is also only approved for use in infants and young children who have a high risk for developing problems with RSV. This includes infants and children who were born prematurely or those with certain types of lung or
heart disease.
Synagis comes as an injection that is given once a month during the RSV season, which usually runs from November to April. As a monoclonal antibody, the drug works by binding to RSV, preventing the virus from multiplying.
(To learn more about indications for this drug, click Synagis Uses. This article further discusses what this medicine is used for and takes a more in-depth look at how it works.)
HealthSavvy Sign In
|